Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 55 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is A  [Clear All Filters]
Journal Article
Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M.  2021.  Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.. BMJ Open Gastroenterol. 8(1)
Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M.  2021.  Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.. BMJ Open Gastroenterol. 8(1)
Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al..  2014.  Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.
Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al..  2021.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.
Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al..  2021.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.
Agrawal M, Zhang W, Lukin D.  2019.  Intestinal Spirochetosis Resembles Inflammatory Bowel Disease in a Patient With HIV Infection.. Clin Gastroenterol Hepatol. 17(6):e60.
Barba-Spaeth G, Longman RS, Albert ML, Rice CM.  2005.  Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.. J Exp Med. 202(9):1179-84.
Stathopoulos C, Jacquin-Becker C, Becker HD, Li T, Ambrogelly A, Longman R, Söll D.  2001.  Methanococcus jannaschii prolyl-cysteinyl-tRNA synthetase possesses overlapping amino acid binding sites.. Biochemistry. 40(1):46-52.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS.  2021.  No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.. Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.
Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML.  2005.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.. J Infect Dis. 192(3):497-503.
Kivolowitz C, Abdulhamid A, Victorio D, Castellanos J, Simpson K, Scherl E, Longman R.  2016.  O-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.. Inflamm Bowel Dis. 22 Suppl 1:S3.
Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML.  2007.  Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients.. J Exp Med. 204(10):2423-37.
Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML.  2007.  Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients.. J Exp Med. 204(10):2423-37.
Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML.  2007.  Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients.. J Exp Med. 204(10):2423-37.
Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM.  2004.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.. Blood. 103(3):1026-9.
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..  2021.  A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
J Blander M, Longman RS, Iliev ID, Sonnenberg GF, Artis D.  2017.  Regulation of inflammation by microbiota interactions with the host.. Nat Immunol. 18(8):851-860.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al..  2017.  Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.
Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al..  2017.  Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.
Koczka CPhilip, Abramowitz M, Goodman AJ.  2012.  The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 24(7):759-61.
Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H.  2015.  Treatment of metastatic cutaneous Crohn disease with certolizumab.. Dermatol Online J. 21(11)
Braun D, Longman RS, Albert ML.  2005.  A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation.. Blood. 106(7):2375-81.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al..  2020.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.